Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Fish and Richardson
Julphar
Accenture
US Army
Boehringer Ingelheim
Johnson and Johnson
Express Scripts
Citi
McKinsey

Generated: February 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,364,473

« Back to Dashboard

Which drugs does patent 9,364,473 protect, and when does it expire?

Patent 9,364,473 protects ONIVYDE and is included in one NDA.

This patent has nineteen patent family members in eighteen countries.
Summary for Patent: 9,364,473
Title:Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
Abstract: Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.
Inventor(s): Bayever; Eliel (Cambridge, MA), Dhindsa; Navreet (Boston, MA), Fitzgerald; Jonathan Basil (Arlington, MA), Laivins; Peter (Scituate, MA), Moyo; Victor (Ringoes, NJ), Niyikiza; Clet (Gulph Mills, PA), Kim; Jaeyeon (Lexington, MA)
Assignee: Merrimack Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:14/844,500
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,364,473

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Ipsen Inc ONIVYDE irinotecan hydrochloride INJECTABLE, LIPOSOMAL;IV (INFUSION) 207793-001 Oct 22, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN, IN A PATIENT HOMOZYGOUS FOR THE UGT1A1*28 ALLELE ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,364,473

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,339,497 Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan ➤ Sign Up
9,717,724 Methods for treating pancreatic cancer using combination therapies ➤ Sign Up
9,452,162 Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan ➤ Sign Up
9,492,442 Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,364,473

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2861210 ➤ Sign Up
Spain 2632915 ➤ Sign Up
Hong Kong 1209627 ➤ Sign Up
Israel 235937 ➤ Sign Up
India 11099DEN2014 ➤ Sign Up
Japan 2015523355 ➤ Sign Up
Japan 2017149783 ➤ Sign Up
South Korea 20150021565 ➤ Sign Up
South Korea 101776808 ➤ Sign Up
South Korea 20170104638 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
US Department of Justice
Medtronic
Harvard Business School
Boehringer Ingelheim
Federal Trade Commission
Daiichi Sankyo
Colorcon
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot